Ajinomoto Co., Inc. · TSE:2802
Ajinomoto — Investor Presentation (October 2024)
23 slides from Ajinomoto's investor presentation, Oct 2, 2024
Slide 1: Forge Biologics, Online Information Session
Ajinomoto Co., Inc. Forge Biologics, Online Information Session Corporate Executive, General Manager, Yasuyuki Otake Bio-Pharma Services Dept. John Maslowski, M.S. President & Chief Executive Officer, Forge Biologics David Dismuke, Ph.D. Chief Technical Officer, Forge Biologics October 2, 2024 (Japa
Slide 2: Overview of Forge Biologics
Overview of Forge Biologics Gene Therapy CDMO 20 cGMP Suites 1L – 5,000L AAV Development and cGMP >200,000L Current Capacity and Ability to Expand Under One Roof Lots Produced >260 +100% YoY Client Growth Approx. 350 Employees 2020 Founded Copyright © 2024 Ajinomoto Co., Inc. All rights reserved. 2
Slide 3: What is Gene Therapy: The Body's Inner Workings
What is Gene Therapy: The Body's Inner Workings • A gene is information encoded through DNA, serving as a blueprint by which the body's cells produce proteins. • Genetic information is copied to messenger RNA (transcription) and based on that information, proteins are created (translation). The prot
Slide 4: What is Gene Therapy: Causes of Genetic Disorders
What is Gene Therapy: Causes of Genetic Disorders • Genetic disorders are caused by an inability to produce proteins with the necessary functions, due to abnormalities in genes. • Gene therapy refers to medical technologies that repair or add the genes contained in cells to treat genetic abnormaliti
Slide 5: What is Gene Therapy: The Principles of AAV Treatment
What is Gene Therapy: The Principles of AAV Treatment • Adeno-associated virus (AAV) vectors are often used as carriers (virus vectors) to introduce genes, designed and manufactured to produce necessary proteins, into target cells in the body. • The introduced therapeutic genes can remain in cells a
Slide 6: Video-1
Ay AJINOMOTO. Video-1
Slide 7: About the AAV Manufacturing Method: Overview of Entire Process
About the AAV Manufacturing Method: Overview of Entire Process 1. Plasmid 2. AAV manufacturing process 3. Filling process manufacturing (production, purification) process Upstream process Downstream process (production) (purification) Manufacture plasmids Culture production Purify AAVs from Fill and
Slide 8: About the AAV Manufacturing Method: The Plasmid Manufacturing Process
About the AAV Manufacturing Method: The Plasmid Manufacturing Process Plasmid Plasmid Introduce into manufacturing microorganisms and amplify Extract and purify ・Prepare three types of plasmids (1) GOI (Gene of Interest) Plasmid Contains target genes for therapeutic efficacy (2) Rep/Cap Plasmid Cont
Slide 9: About the AAV Manufacturing Method: The AAV Manufacturing Process
About the AAV Manufacturing Method: The AAV Manufacturing Process ・Multiply mammalian cells used in AAV production Upstream process (production) Multiplication Ignition Cells™ ・HEK293 mammalian cell line, developed Forge Biologics' by Forge Biologics proprietary = Realize high stability and ・High st
Slide 10: About the AAV Manufacturing Method: The AAV Manufacturing Process
About the AAV Manufacturing Method: The AAV Manufacturing Process ・Introduce three types of prepared plasmids and produce AAVs Upstream process (production) AAV pEMBR™ GOI Rep/Cap Ignition Cells™ Transfection (introduction of AAV plasmids) production Copyright © 2024 Ajinomoto Co., Inc. All rights r
Slide 11: About the AAV Manufacturing Method: The AAV Manufacturing Process – Filling
About the AAV Manufacturing Method: The AAV Manufacturing Process – Filling ・Refine AAVs and fill Downstream process Filling process AAV Separation and purification Copyright © 2024 Ajinomoto Co., Inc. All rights reserved. 11
Slide 12: Video-2
Ay AJINOMOTO. Video-2
Slide 13: Rapid Growing Gene Therapy CDMO Market
Rapid Growing Gene Therapy CDMO Market Gene therapy market is expected to grow rapidly at double-digit rates annually, driven by expanding market size and increasing clinical trials. Cell and Gene Therapy TAM 1 ($bn) AAV Clinical Trials 226 Cell & Gene Therapy TAM (excl. AAV) 2030 est.: $46bn 202 28
Slide 14: Forge Biologics' Customer Acquisition Status and Sales Forecast
Forge Biologics' Customer Acquisition Status and Sales Forecast • Under an improved financing environment in North America, orders in the April to July period of FY2024 were approximately 2.5x that of the same period last year. • Compared to FY2023, sales are expected to grow over 2x in FY2024 and a
Slide 15: Forge Biologics' High-Level Expertise and Diverse Human Resources
Forge Biologics’ High-Level Expertise and Diverse Human Resources • Forge Biologics has many highly experienced experts in the field of gene therapy, with over 50 Ph.D holders, including within top management. The company's retention rate is also high. • In Ohio, USA, a world leading region in the f
Slide 16: High Affinity between AminoScience and Forge Biologics' Technologies
High Affinity between “AminoScience” and Forge Biologics' Technologies • Launched a synergy team through collaboration between Ajinomoto Co. and Forge Biologics AAV manufacturing know-how. High-level technology foundation in the CDMO field. Unique platform technology. Cultivated manufacturing know-h
Slide 17: Supply Chain Optimization
Supply Chain Optimization Optimization of the supply chain in the North American Bio-Pharma business with the acquisition of Forge Biologics Ajinomoto Althea, Inc. Forge Biologics Liquid High-potency AAV based AAV preparations preparations APIs preparations Transfer, consolidate Manufacturing of API
Slide 18: Synergies with Bio-Pharma Business Global Sites
Synergies with Bio-Pharma Business Global Sites • Enhancement of reliability by becoming a member of the Ajinomoto Group and strengthening its management foundation • Increase in points of contact with customers by utilizing the Ajinomoto Bio-Pharma Services network that spans Japan, the United Stat
Slide 19: Growth Strategy in the Healthcare Area
Growth Strategy in the Healthcare Area Acquisition of Forge Biologics and Expansion With the acquisition of Forge, we acquired the business foundation and unique differentiating technology of a gene therapy CDMO, and gained a foothold to strengthen and create business through synergies and expand in
Slide 20: Forward-looking statements
Forward-looking本資料に記載されている業績見通し等の将来に関する記載は、 statements, such as business performance forecasts, made in these materials 本資料の発表日現在における将来の見通し、計画のもととなる前提、 are based on management's estimates, assumptions and 予測を含んで記載しており、当社としてその実現を約束する趣旨の projections at the time of publication. A number of factors coul
Slide 21: Glossary ①
Glossary ① Term Meaning and details Transcription The process by which the genetic information in DNA is copied to and translation messenger RNA (mRNA) is called "transcription." The process by which the information that was copied to mRNA is converted into a sequence of amino acids, the amino acids
Slide 22: Glossary ②
Glossary ② Term Meaning and details GMP suite GMP stands for "Good Manufacturing Practice," referring to standards and rules established to ensure product quality. A GMP suite is a special room in which specific rules and criteria are in place, used for the production of viral vectors for gene thera
Slide 23: Glossary ③
Glossary ③ Term Meaning and details Ignition Cell ™ Forge Biologic's proprietary HEK293 cell strain for the manufacture of virus vectors. The strain demonstrates stable transfection efficiency and high AAV production efficiency. It also meets various regulatory standards and the cell bank is certifi